TW202241944A - 新穎的抗ｇｒｅｍｌｉｎ１抗體 - Google Patents

新穎的抗ｇｒｅｍｌｉｎ１抗體 Download PDF

Info

Publication number
TW202241944A
TW202241944A TW111102041A TW111102041A TW202241944A TW 202241944 A TW202241944 A TW 202241944A TW 111102041 A TW111102041 A TW 111102041A TW 111102041 A TW111102041 A TW 111102041A TW 202241944 A TW202241944 A TW 202241944A
Authority
TW
Taiwan
Prior art keywords
seq
sequence
cancer
chain variable
variable region
Prior art date
Application number
TW111102041A
Other languages
English (en)
Chinese (zh)
Inventor
雪明 錢
崔素麗
李紅俊
孫迪
郭歡歡
Original Assignee
中國大陸商蘇州創勝醫藥集團有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 中國大陸商蘇州創勝醫藥集團有限公司 filed Critical 中國大陸商蘇州創勝醫藥集團有限公司
Publication of TW202241944A publication Critical patent/TW202241944A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW111102041A 2021-01-18 2022-01-18 新穎的抗ｇｒｅｍｌｉｎ１抗體 TW202241944A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
WOPCT/CN2021/072397 2021-01-18
CN2021072397 2021-01-18
CN2021142043 2021-12-28
WOPCT/CN2021/142043 2021-12-28

Publications (1)

Publication Number Publication Date
TW202241944A true TW202241944A (zh) 2022-11-01

Family

ID=82446960

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111102041A TW202241944A (zh) 2021-01-18 2022-01-18 新穎的抗ｇｒｅｍｌｉｎ１抗體

Country Status (10)

Country Link
US (1) US20240294622A1 (enExample)
EP (1) EP4277927A4 (enExample)
JP (1) JP7879131B2 (enExample)
KR (1) KR20230132544A (enExample)
CN (1) CN116848135A (enExample)
AU (1) AU2022207030A1 (enExample)
CA (1) CA3208455A1 (enExample)
MX (1) MX2023008423A (enExample)
TW (1) TW202241944A (enExample)
WO (1) WO2022152290A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230156936A (ko) * 2021-03-11 2023-11-15 상하이 지아오통 대학 그렘린1 길항제를 사용하여 질환을 치료하는 방법
GB202205203D0 (en) * 2022-04-08 2022-05-25 UCB Biopharma SRL Combination with inhibitor
GB202205200D0 (en) * 2022-04-08 2022-05-25 Ucb Biopharma Sprl Combination with chemotherapy
KR20250169623A (ko) * 2023-04-13 2025-12-03 쑤저우 트랜스센타 테라퓨틱스 컴퍼니 리미티드 암 치료를 위한 grem1 길항제를 수반하는 조합 요법
TW202541848A (zh) * 2024-01-08 2025-11-01 中國大陸商蘇州創勝醫藥集團有限公司 用於治療ｐａｈ之ｇｒｅｍ１拮抗劑及活化素受體拮抗劑的組合療法
CN117801109B (zh) * 2024-03-01 2024-05-03 再少年(北京)生物科技有限公司 iPS诱导定向分化成内皮祖细胞的方法及应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013137686A1 (ko) 2012-03-15 2013-09-19 서울대학교 산학협력단 그렘린-1에 대한 항체
BR112015021979A2 (pt) * 2013-03-14 2017-08-29 Regeneron Pharma Anticorpos humanos para grem1
CN109641954A (zh) 2016-08-29 2019-04-16 里珍纳龙药品有限公司 抗-gremlin-1(grem1)抗体及其用于治疗肺动脉高血压的使用方法
GB201621635D0 (en) 2016-12-19 2017-02-01 Ucb Biopharma Sprl Crystal structure
AU2019289176B2 (en) 2018-06-18 2026-02-19 Adelaide university Gremlin-1 antagonist for the prevention and treatment of cancer
KR20230156936A (ko) * 2021-03-11 2023-11-15 상하이 지아오통 대학 그렘린1 길항제를 사용하여 질환을 치료하는 방법

Also Published As

Publication number Publication date
JP2024504124A (ja) 2024-01-30
CA3208455A1 (en) 2022-07-21
JP7879131B2 (ja) 2026-06-23
MX2023008423A (es) 2023-07-26
US20240294622A1 (en) 2024-09-05
EP4277927A1 (en) 2023-11-22
EP4277927A4 (en) 2025-07-23
AU2022207030A9 (en) 2024-09-19
AU2022207030A1 (en) 2023-08-24
KR20230132544A (ko) 2023-09-15
CN116848135A (zh) 2023-10-03
WO2022152290A1 (en) 2022-07-21

Similar Documents

Publication Publication Date Title
US11753473B2 (en) Anti-PD-L1 antibodies
CN102421802B (zh) 人源化的axl抗体
TWI854953B (zh) 抗ｃｄ３抗體及含有該抗體的分子、及其製造方法
US20240294622A1 (en) Novel anti-gremlin1 antibodies
WO2021185273A1 (zh) 靶向Sirpα的抗体或其抗原结合片段及其制备和应用
CN112225812B (zh) 结合tfpi的新型抗体以及包含所述抗体的组合物
US20250136720A1 (en) Bispecific and tetravalent cd137 and fap molecules for the treatment of cancer
KR20220042258A (ko) 항 tigit 항체 및 그의 응용
EP4663660A1 (en) Trispecific antigen-binding molecule and use thereof
TW202330600A (zh) Fap/cd40 結合分子及其醫藥用途
TW202304997A (zh) 新型抗ｃｄ４抗體
KR20220167331A (ko) 항-flt3 항체 및 조성물
HK40093421A (zh) 新颖的抗gremlin1抗体
US20240301061A1 (en) Anti-cldn6 and anti-cd3 multispecific antibodies and methods of use
WO2025195358A1 (zh) Pd-1结合蛋白及医药用途
CN121057749A (zh) 抗cd3多特异性抗体和使用方法
HK40032298A (en) Novel anti-pd-l1 antibodies
HK40032298B (en) Novel anti-pd-l1 antibodies
HK1260737A1 (en) Novel anti-pd-l1 antibodies
HK1260737B (en) Novel anti-pd-l1 antibodies